NextPlat Cuts Q1 Net Loss 42% as Record 35% Gross Margin Boosts Outlook
NextPlat reported Q1 revenue of $9.9 million, down 29% year-over-year, while achieving a record consolidated gross margin of 35%, up from 21% a year ago. Operating expenses fell 9% to $4.5 million, driving a 42% reduction in net loss to $1.1 million and underpinning an expected positive operating income in H2 2026.
1. Q1 Financial Performance
NextPlat generated consolidated revenue of $9.9 million for Q1 2026, down 29% from $13.9 million a year earlier, reflecting lower healthcare prescription reimbursements. Healthcare pharmacy contract revenue rose to $1.9 million, up 19% sequentially, while e-commerce sales increased to $3.2 million due to higher airtime product demand.
2. Margin Improvement Drivers
Gross margin expanded dramatically to 35% in Q1, a quarterly record, driven by higher-margin 340B and contracted medication fulfillment services and improved drug costing under the new Medicare Maximum Fair Price program. Healthcare operations margin nearly doubled to 39%, while e-commerce margin ticked up to 25%.
3. Expense Reductions and Cash Position
Total operating expenses declined 9% to $4.5 million through headcount and professional fee reductions, helping lower the net loss by 42% to $1.1 million, or $(0.42) per share. The company closed the quarter with $11.0 million in cash, $14.2 million in working capital and zero unsecured debt.
4. Outlook and Strategic Initiatives
Management expects positive operating income in the latter half of 2026, fueled by ongoing cost discipline and higher-margin healthcare services. A new nationwide pharmacy fulfillment partnership and upcoming healthcare e-commerce site launch are set to expand addressable markets and support sustained growth.